Complications of Therapies

Slide 1 · Complications of Therapies

Pulmonary complications of medical treatment

Drug-induced lung disease

Radiation pneumonitis and pulmonary fibrosis

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Recognize the major pulmonary injury patterns linked to therapies.

Explain how selected drugs and thoracic irradiation produce lung injury.

Connect exposure history, pathology, clinical effects, and disease evolution.

Distinguish acute pneumonitis from chronic fibrotic sequelae.

Slide 3 · Therapeutic exposure can injure several lung compartments

Drug or irradiation

Epithelial, interstitial or vascular injury

Inflammatory response

Functional impairment / fibrosis

Simplified causal pathway / teaching schema

Slide 4 · Two sources of therapy-associated pulmonary injury

Drug-associated

Cytotoxic agents, antiarrhythmics, antimicrobials, ACE inhibitors; Injected particulates

Radiation-associated

Lung damage after irradiation for intrathoracic or adjacent tumors

Slide 5 · Therapy complications: Morphology is heterogeneous

Compartment / pattern

Illustrative lesion

Relevant exposure

Interstitial tissue

Pulmonary fibrosis

Bleomycin; nitrofurantoin

Small airways

Bronchiolitis obliterans

Drug-associated pattern (class-level)

Airspaces / interstitium

Eosinophilic pneumonia

Drug-associated pattern (class-level)

Microvasculature

Foreign-particle granulomas

Intravenous drug adulterants

Slide 6 · The affected anatomical compartment shapes pathology

Alveolar interstitium

Small airway

Microvasculature

Septum

Airway lumen

Vascular wall

Schematic • tissue compartments, not representative histologic sections

Slide 7 · Therapeutic injury is not one histologic diagnosis

Different drugs may produce different structural patterns of damage.

One pattern can have several alternative causes.

A treatment history is therefore essential to interpret nonspecific lung injury.

Interpret the tissue pattern together with timing and exposure.

Slide 8 · Think in terms of injury, repair and sequelae

Initial insult

Therapy-related tissue injury

Inflammatory phase

Pneumonitis or alveolitis

Outcome

Resolution or persistent fibrosis

Slide 9 · Clinical interpretation begins with treatment history

Document the precise drug or radiotherapy exposure.

Determine whether symptoms started during or after treatment.

Ask whether injury localizes to the radiation field.

Avoid assigning causation from exposure alone.

Slide 10 · Therapeutic lung disease versus competing processes

Supports therapy-related injury

Temporally plausible exposure; Matching distribution; Compatible lung-injury pattern

Requires separate consideration

Infection, malignancy-related disease, or other interstitial lung disorders

Slide 11 · Drug-associated pulmonary pathology: Recognized patterns

Interstitial fibrosis alters parenchymal compliance and gas exchange.

Bronchiolitis obliterans narrows or obstructs small airways.

Eosinophilic pneumonia is an inflammatory airspace / interstitial pattern.

These manifestations are patterns of injury, not agent-specific signatures.

Slide 12 · Three morphologic drug-injury patterns

Interstitial fibrosis

Expanded septal tissue

Bronchiolitis obliterans

Narrowed airway lumen

Eosinophilic pneumonia

Inflammatory airspace pattern

Simplified compartment-based illustrations; No morphologic specimen represented

Slide 13 · Bleomycin: A cytotoxic pulmonary exposure

Bleomycin is used as an antineoplastic cytotoxic drug.

It as an example of drug-induced pulmonary damage.

A clinically important sequela is pulmonary fibrosis.

Pulmonary toxicity is separate from the intended antitumor effect.

Slide 14 · Bleomycin injury has direct and inflammatory components

Bleomycin exposure

Direct pulmonary cellular toxicity

Inflammatory-cell influx into alveoli

Pulmonary injury and fibrosis

Simplified causal pathway / teaching schema

Slide 15 · Direct toxicity and alveolar inflammation can coexist

Direct injury

Inflammatory influx

Injury plus scarring

Slide 16 · Bleomycin: Interpreting a fibrotic endpoint

Fibrosis denotes deposition of persistent interstitial connective tissue.

Progressive remodeling may interfere with alveolar gas exchange.

A fibrotic lesion alone cannot prove prior bleomycin exposure.

Correlation with chemotherapy history is required.

Slide 17 · Mechanism and outcome are different levels of explanation

Mechanism

Direct cytotoxic injury and inflammatory recruitment explain how damage begins

Morphologic endpoint

Interstitial fibrosis records a potentially persistent tissue response

Slide 18 · Case: Dyspnea after cancer chemotherapy

A patient receives a bleomycin-containing cancer regimen.

Respiratory symptoms subsequently arise, with evidence of interstitial lung injury.

Which causal mechanisms are relevant?

What can and cannot be concluded from fibrosis alone?

Slide 19 · Case interpretation: Bleomycin-associated injury

Bleomycin is a plausible etiologic exposure in this clinical setting.

Both direct toxicity and inflammatory recruitment.

Fibrosis is compatible with the described injury endpoint.

Temporal association and compatible morphology support—but do not alone establish—causation.

Slide 20 · Amiodarone: Pulmonary accumulation matters

Amiodarone is used to treat cardiac arrhythmias.

The drug preferentially concentrates in pulmonary tissue.

The textbook associates this accumulation with significant pneumonitis.

The clinical lesion differs conceptually from uncomplicated medication-related cough.

Slide 21 · Amiodarone: Interpret the quoted frequency carefully

Robbins statement

Interpretation

Significant pneumonitis: 5%–15%

Textbook-reported range in exposed patients

Pulmonary accumulation

Important exposure characteristic

Applicability

Not a personalized risk estimate or universal rate

Slide 22 · Amiodarone: Tissue exposure and pneumonitis

Amiodarone exposure

Preferential lung accumulation

Significant pneumonitis

Robbins association shown without unsupported pharmacologic mechanism

Slide 23 · Amiodarone pneumonitis: Clinicopathologic reasoning

The therapeutic indication is cardiac arrhythmia.

A pulmonary complication can develop despite use for a nonpulmonary disease.

The diagnosis should be considered when compatible lung injury follows exposure.

Do not treat every new respiratory symptom in a treated patient as drug toxicity.

Slide 24 · Bleomycin and amiodarone: Distinguish the emphasis

Bleomycin

Cytotoxic cancer drug; Direct injury plus inflammatory recruitment; Pulmonary fibrosis

Amiodarone

Antiarrhythmic with lung accumulation; Significant pneumonitis described

Slide 25 · Nitrofurantoin: An antimicrobial linked to fibrosis

Nitrofurantoin is used to treat urinary tract infection.

Robbins explicitly links this agent to pulmonary fibrosis.

A nononcologic prescription can therefore be relevant to interstitial lung disease.

Source does not specify dose, latency or a unique tissue signature.

Slide 26 · Different clinical indications, convergent lung findings

Anticancer exposure

Bleomycin: Damage and fibrosis

Antimicrobial exposure

Nitrofurantoin: Associated pulmonary fibrosis

Slide 27 · ACE-inhibitor cough: An important distinction

Angiotensin-converting enzyme inhibitor–induced cough is common.

Cough alone is a symptom, not evidence of pulmonary fibrosis.

A cough-predominant adverse effect must not be conflated with interstitial pneumonitis.

The Robbins paragraph does not specify the mechanism of ACE-inhibitor cough.

Slide 28 · A symptom cannot be substituted for a tissue pattern

Clinical or tissue finding

What it establishes

Cough after ACE inhibitor

Recognized treatment-associated symptom

Pneumonitis after amiodarone

Potential parenchymal inflammatory injury

Fibrosis after bleomycin

Potential chronic structural tissue response

Slide 29 · Intravenous drug use: Infectious injury predominates

The most frequent pulmonary complications are infections.

This pathway is distinct from direct pharmaceutical toxicity.

A patient may also develop noninfectious injury from injected particulate material.

Both mechanisms must be recognized when interpreting lung pathology.

Slide 30 · Injected insoluble particles can lodge in small lung vessels

Particulate drug adulterant

Intravenous delivery

Pulmonary microvascular lodging

Granulomatous inflammation and fibrosis

Simplified causal pathway / teaching schema

Slide 31 · Foreign-particle lung disease centers on the microvasculature

Particulate retention → granulomatous response

Vessel wall

Schematic site of injury; Not polarized-light or H&E histology

Slide 32 · Why particulate deposits provoke granulomatous change

Particulate material lodges in the pulmonary microvascular bed.

The tissue response may include granulomatous inflammation.

Fibrosis may accumulate around the resulting chronic lesions.

This distribution should prompt a search for an intravascular exposure history.

Slide 33 · Injection-related pulmonary complications: Two pathways

Infectious

Infection is the most frequent pulmonary complication

Noninfectious

Microvascular particulates may provoke granulomas and fibrosis

Slide 34 · Case: Particulate-associated lung granulomas

A lung specimen shows a granulomatous response around small vascular structures.

The clinical history includes intravenous administration of adulterated substances.

Which exposure pathway accounts for the distribution?

What other common pulmonary complication must be considered?

Slide 35 · Case interpretation: Vascular particulate injury

Injected particles can travel to and lodge within pulmonary microvasculature.

The resulting tissue response may be granulomatous and fibrotic.

The vascular distribution supports this exposure hypothesis.

Infection remains a major competing or coexisting pulmonary problem.

Slide 36 · Drug-related patterns: Do not overassign specificity

Exposure

Textbook-supported association

Bleomycin

Damage via direct and inflammatory mechanisms; fibrosis

Amiodarone

Pulmonary concentration; significant pneumonitis

Nitrofurantoin

Pulmonary fibrosis

ACE inhibitors

Cough

Injected particulates

Microvascular granulomas and fibrosis

Slide 37 · Radiotherapy can injure lung near the tumor

Thoracic radiotherapy is used for tumors of lung, esophagus, breast and mediastinum.

Radiation pneumonitis is a recognized complication.

Injury most commonly involves lung within the irradiated field.

Acute and chronic pulmonary forms are described.

Slide 38 · Irradiation field predicts the distribution of injury

Radiation field

Irradiated pulmonary tissue

Stylized projection field only; Patient-specific beam geometry varies

Slide 39 · Acute and chronic radiation lung disease

Acute radiation pneumonitis

Inflammatory / alveolar injury after therapy, with possible systemic symptoms

Chronic radiation injury

Pulmonary fibrosis; May follow acute illness or appear without recognized acute pneumonitis

Slide 40 · Radiation injury has a clinically important time course

Radiotherapy

Thoracic irradiation

1–6 months

Acute pneumonitis may become apparent

Later evolution

Resolution or chronic fibrosis

Slide 41 · Timing: Acute radiation pneumonitis

The acute clinical syndrome at 1–6 months after irradiation.

Latency should be considered alongside the radiation field.

Symptoms outside this temporal framework need broader interpretation.

Latency alone is insufficient to diagnose radiation pneumonitis.

Slide 42 · Radiation pneumonitis frequency varies widely

Parameter in Robbins

Reported detail

Acute pneumonitis frequency

3%–44% of patients

Important modifiers stated

Radiation dose and patient age

Interpretation

Broad reported range; not a single universal event rate

Slide 43 · Acute radiation pneumonitis: Symptoms

Fever may accompany the inflammatory lung process.

Dyspnea can be marked, even relative to irradiated lung volume.

Pleural effusion is a recognized accompanying manifestation.

Pulmonary infiltrates may be present on imaging.

Slide 44 · Clinical and imaging clues are complementary

Clinical presentation

Fever and disproportionate dyspnea after thoracic irradiation

Anatomic evidence

Pulmonary infiltrates and sometimes pleural effusion; Relation to treatment field

Slide 45 · Dyspnea may exceed the visible field volume

The reported acute syndrome may cause severe respiratory symptoms.

Symptom intensity need not match the small apparent irradiated volume.

Severity must not be dismissed solely because the geometric field is limited.

Clinical and radiologic findings require integrated assessment.

Slide 46 · Diffuse alveolar damage is the acute injury pattern

Airspace edema

Hyaline membrane

Epithelial damage

Slide 47 · Radiation injury shows reactive epithelial atypia

Hyperplastic type II pneumocytes may show nuclear atypia.

These changes occur in an injured and regenerating alveolar epithelium.

Radiation-associated epithelial atypia must be interpreted in exposure context.

Cytologic atypia is not by itself proof of a neoplasm.

Slide 48 · Injury-related atypia is part of the radiation pattern

Baseline epithelial cell

Reactive type II cell

Atypical fibroblast

Cell outlines purely illustrative; Not histologic diagnostic criteria or morphology at scale

Slide 49 · Reactive fibroblasts may also appear atypical

Atypia of fibroblasts alongside type II pneumocytes.

The stromal compartment can therefore show treatment-related changes.

The finding is interpreted alongside alveolar damage and treatment history.

No stand-alone microscopic criterion is specified in the supplied paragraph.

Slide 50 · Foam cells in vessel walls: A vascular clue

Foam cells within vessel wall

Vessel wall

Schematic site of injury; Not polarized-light or H&E histology

Slide 51 · Characteristic vascular finding after irradiation

Foam cells may appear within pulmonary vessel walls.

The source describes this as characteristic of radiation injury.

Epithelial atypia may accompany the vascular finding.

Assess these findings as a constellation rather than isolated pathognomonic signs.

Slide 52 · Morphologic constellation in acute radiation injury

Tissue component

Change described by Robbins

Alveoli

Diffuse alveolar damage

Type II pneumocytes

Hyperplasia and atypia

Stroma

Atypical fibroblasts

Vascular walls

Foam cells

Slide 53 · Steroid-treated acute illness has two possible courses

Acute radiation pneumonitis

Complete symptomatic resolution in some

Chronic fibrosis in other patients

Corticosteroid treatment may be followed by recovery; Fibrosis may also arise without a recognized acute episode.

Slide 54 · Two outcomes after radiation pneumonitis

Potentially reversible

Symptoms may resolve completely with steroid therapy

Potentially persistent

Other cases progress to chronic pneumonitis and fibrosis

Slide 55 · Chronic fibrosis may appear without overt acute illness

Chronic radiation pneumonitis represents a fibrosing pulmonary outcome.

An antecedent clinically apparent acute episode is not mandatory.

Absence of recorded acute pneumonitis does not exclude later fibrosis.

Review the irradiation history when interpreting chronic regional scarring.

Slide 56 · From alveolar injury to fixed interstitial fibrosis

Injured alveolus

Chronic injury

Fibrotic septum

Slide 57 · Advanced radiation fibrosis can burden the right heart

Progressive lung fibrosis

Impaired pulmonary circulation

Pulmonary hypertension

Cor pulmonale

Simplified causal pathway / teaching schema

Slide 58 · Severe chronic radiation injury: Clinical consequences

Progressive pulmonary fibrosis can impair respiratory function.

Cyanosis may appear in the most severe disease.

Pulmonary hypertension may develop.

Cor pulmonale represents an important terminal cardiopulmonary complication.

Slide 59 · Drug toxicity and radiation injury: Contrasting clues

Dimension

Drug-associated

Radiation-associated

Exposure clue

Drug name and treatment history

Thoracic irradiation and field

Distribution

Varies by agent / process

Often within radiation field

Important examples

Fibrosis, pneumonitis, cough, vascular granulomas

Acute pneumonitis, later fibrosis

Microscopic clues

Agent- and pattern-dependent

DAD plus atypia and vascular foam cells

Slide 60 · Case: Delayed dyspnea after breast irradiation

Several months after thoracic irradiation for a breast malignancy, a patient develops fever and dyspnea.

Chest imaging demonstrates a pulmonary infiltrate close to the treatment region.

Which acute complication is plausible?

Which tissue changes would support the suspected injury?

Slide 61 · Case interpretation: Acute radiation pneumonitis

Thoracic irradiation and a compatible delay support the exposure link.

Fever, dyspnea and infiltrates align with the textbook syndrome.

Diffuse alveolar damage, type II-cell/fibroblast atypia and vascular foam cells are described morphologic clues.

The case still requires consideration of alternative causes of new infiltrates.

Slide 62 · Case: Pulmonary fibrosis without a recognized acute phase

A patient previously received mediastinal irradiation.

Chronic pulmonary scarring develops without documented acute pneumonitis.

Does the missing acute episode refute radiation-associated fibrosis?

What severe cardiopulmonary sequelae could follow progression?

Slide 63 · Case interpretation: Chronic radiation injury

No: Chronic fibrosis may occur without an overt preceding acute syndrome.

Progressive disease can cause cyanosis and pulmonary hypertension.

Severe pulmonary vascular loading can lead to cor pulmonale.

Interpret the fibrosis in relation to the irradiated anatomy and other causes.

Slide 64 · Avoid five common interpretation errors

Do not confuse a symptom (cough) with a histologic pattern (fibrosis).

Do not treat a broad published frequency range as an individual risk.

Do not assume any atypical irradiated cell is malignant.

Do not require a documented acute episode before considering chronic radiation fibrosis.

Do not label a nonspecific injury pattern without an exposure history.

Slide 65 · A practical clinicopathologic reasoning sequence

Identify exposure

Establish timing and distribution

Classify tissue-injury pattern

Consider alternative causes

Integrate evidence

Simplified causal pathway / teaching schema

Slide 66 · High-yield associations for rapid recall

Therapy / exposure

Core association

Bleomycin

Direct plus inflammatory injury → pulmonary fibrosis

Amiodarone

Lung concentration → pneumonitis

Nitrofurantoin

Pulmonary fibrosis

ACE inhibitors

Common cough

Intravenous particulates

Microvascular granulomas / fibrosis

Thoracic radiation

Acute pneumonitis or chronic fibrosis

Slide 67 · Synthesis: Three principles to retain

Therapy-related pulmonary disease spans multiple tissue compartments.

The medication or radiation history provides etiologic context, not a stand-alone diagnosis.

Acute inflammatory damage may resolve or evolve to lasting fibrosis.

Severe chronic fibrosis can culminate in pulmonary hypertension and cor pulmonale.

Slide 68 · Principal references and scope

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026), Chapter 15, “Complications of Therapies.”

Related Chapter 15 sections: diffuse alveolar damage, airway injury, and interstitial disease provide explanatory context.

Mechanism schematics and hypothetical cases are original instructional interpretations of the textbook.

No textbook photomicrographs or third-party clinical images have been reproduced.